Welcome to our dedicated page for Rein Therapeutics SEC filings (Ticker: RNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding a clinical-stage biotech filing can feel like translating a different language. Rein Therapeutics鈥� 10-K doesn鈥檛 just list numbers鈥攊t hides crucial clues about LTI-03 trial timelines, orphan-drug exclusivity, and how long the company鈥檚 cash runway will last. That鈥檚 why investors search for 鈥淩ein Therapeutics SEC filings explained simply鈥� and 鈥淩ein Therapeutics annual report 10-K simplified.鈥�
Stock Titan solves the problem. Our AI engine turns every Rein Therapeutics quarterly earnings report 10-Q filing into a clear summary that highlights R&D spend, dilution risk, and pipeline progress. Need to follow sudden disclosures? The platform flags each Rein Therapeutics 8-K material events explained within minutes of hitting EDGAR. Curious about management鈥檚 confidence? Get instant alerts on Rein Therapeutics Form 4 insider transactions real-time, so you can track executive stock transactions Form 4 before the market reacts.
Everything appears in one place:
- Annual filings: Rein Therapeutics annual report 10-K simplified with AI notes on cash burn and FDA interactions.
- Quarterly reports: Rein Therapeutics earnings report filing analysis for quick quarter-over-quarter comparisons.
- Current reports: Rein Therapeutics 8-K updates on trial data, licensing deals, or financing rounds.
- Insider activity: Rein Therapeutics insider trading Form 4 transactions monitored continuously.
- Governance: Rein Therapeutics proxy statement executive compensation broken down into salary, options, and milestone grants.
Stop wading through jargon. With Stock Titan you鈥檙e understanding Rein Therapeutics SEC documents with AI鈥攊n real time, with the details that matter to biotech investors.
On 29 Jul 2025 Rein Therapeutics (RNTX) entered two financing arrangements with YA II PN, Ltd. 1) Pre-Paid Advance Agreement (PPA): the company can draw up to $6.0 m over 12 months; Yorkville purchases each advance at 95% of face value (initial draw $1.0 m yielded $0.95 m). Interest accrues at 8% (18% upon default). Yorkville may force repayment in shares at the lower of 115% of prior-day VWAP or 95% of the lowest VWAP in the prior 7 trading days, but not below a $0.28 floor. Floor-price, registration-effectiveness or exchange-cap breaches trigger monthly cash amortization of up to 25% of the original advance.
2) Standby Equity Purchase Agreement (SEPA): provides an equity line of up to $15.0 m over 36 months. Each advance is priced at 96% of the lowest VWAP during the three days after an advance notice, subject to volume and minimum-price limits. Rein paid a $300 k commitment fee via 213,099 shares and $25 k expenses.
The aggregate shares issuable under both facilities are capped at 19.9% of current outstanding stock, and Yorkville鈥檚 ownership is limited to 4.99%. PPA shares will be issued off the company鈥檚 shelf registration; SEPA shares require an effective resale registration statement. The facilities give Rein up to ~$21 m in gross liquidity with flexible timing, but at the cost of discounted pricing, possible dilution and potential downward pressure on the share price.
Rein Therapeutics (Nasdaq: RNTX) filed a Rule 424(b)(5) prospectus supplement that amends its May 22 2025 at-the-market (ATM) shelf with H.C. Wainwright.
The filing reduces the remaining issuance capacity under the Form S-3 from $15.77 million to $8.07 million. The cut aligns with General Instruction I.B.6, which limits sales to one-third of the company鈥檚 $42.3 million public float (calculated on July 24 2025) during any 12-month period while the float remains below $75 million.
To date the company has raised only $35,460 (16,127 shares) through the ATM. Following the adjustment, up to approximately $8.03 million of common stock can still be issued from time to time. Additional supplements will be required if a larger float later permits greater issuance capacity.
RNTX shares last closed at $1.41 on July 28 2025. Investors should evaluate the dilution risk associated with future ATM sales versus the financing flexibility this mechanism provides.
Form 4 filing: Rein Therapeutics (RNTX) disclosed that director Manuel Aivado was granted a stock option for 17,500 common shares on 23-Jul-2025 at an exercise price of $1.55 per share, expiring 22-Jul-2035.
The option vests 100 % on the earlier of 23-Jul-2026 or the 2026 annual meeting, subject to continued board service. No open-market purchases or sales of common stock were reported, and Aivado鈥檚 post-transaction derivative holdings total 17,500 options, all held directly.
This is a routine equity-based compensation grant that does not immediately alter the public float or cash position. If exercised, the award would introduce only modest dilution, typical for small-cap governance practices, while further aligning the director鈥檚 interests with shareholders.
Rein Therapeutics (RNTX) filed a Form 4 disclosing a routine equity grant to independent director Alan A. Musso. On 07/23/2025 Musso received 17,500 non-qualified stock options exercisable at $1.55 per share, equal to the grant-date market price. The award vests 100 % on the earlier of 07/23/2026 or the company鈥檚 2026 annual meeting, conditional on continued board service. Following the transaction Musso beneficially owns 17,500 derivative securities and no additional common shares were reported. Ownership is held directly; no indirect holdings were disclosed.
No sale of shares, cashless exercise, or change in overall insider ownership occurred, so immediate dilution is de-minimis. The filing is primarily administrative, aligning director incentives with shareholders.
Rein Therapeutics, Inc. (RNTX) 鈥� Form 4 insider filing
Director William C. Fairey reported the grant of 17,500 non-qualified stock options on 07/23/2025. The options carry a $1.55 exercise price and will vest in full on the earlier of 07/23/2026 or the company鈥檚 2026 annual shareholder meeting, provided the director remains in service. The options expire on 07/22/2035. No common shares were bought or sold and the filing shows direct ownership of the new derivative position. This appears to be routine board compensation and does not alter the company鈥檚 capital structure or provide guidance on operating performance.
Rein Therapeutics (RNTX) filed a Form 4 on 23-Jul-2025 reporting the first equity award to director Reinhard J. Ambros. The filing shows a single transaction: a stock-option grant for 17,500 common shares at an exercise price of $1.55 per share. The option vests 100% on the earlier of 23-Jul-2026 or the company鈥檚 2026 annual meeting, contingent on continued service. No sales or open-market purchases were disclosed, and Table I lists no direct common-stock holdings. After the grant, Ambros鈥� beneficial ownership consists of 17,500 derivative securities held directly.
The transaction is routine director compensation and represents a modest potential dilution relative to RNTX鈥檚 total share count (not provided in the filing). Because it is an A code (award) rather than an open-market buy, it should not be interpreted as an active insider purchase. However, it does increase insider alignment by giving the director upside participation tied to share-price performance above $1.55.
FAQ
What is the current stock price of Rein Therapeutics (RNTX)?
What is the market cap of Rein Therapeutics (RNTX)?
